Recent advances in the use of liquid biopsy to fight central nervous system tumors

Q3 Medicine

Cancer treatment and research communications Pub Date : 2023-01-01 DOI:10.1016/j.ctarc.2023.100709

Carlos Pilotto Heming, Paulo Niemeyer Filho, Vivaldo Moura-Neto, Veronica Aran

{"title":"Recent advances in the use of liquid biopsy to fight central nervous system tumors","authors":"Carlos Pilotto Heming, Paulo Niemeyer Filho, Vivaldo Moura-Neto, Veronica Aran","doi":"10.1016/j.ctarc.2023.100709","DOIUrl":null,"url":null,"abstract":"<div><p>Brain tumors are considered one of the deadliest types of cancer, being challenging to treat, especially due to the blood-brain barrier, which has been linked to treatment resistance. The genomic classification of brain tumors has been helping in the diagnostic precision, however tumor heterogeneity in addition to the difficulties to obtain tissue biopsies, represent a challenge. The biopsies are usually obtained either via neurosurgical removal or stereotactic tissue biopsy, which can be risky procedures for the patient. To overcome these challenges, liquid biopsy has become an interesting option by constituting a safer procedure than conventional biopsy, which may offer valuable cellular and molecular information representative of the whole organism. Besides, it is relatively easy to obtain such as in the case of blood (venipuncture) and urine sample collection. In the present comprehensive review, we discuss the newest information regarding liquid biopsy in the brain tumors’ field, methods employed, the different sources of bio-fluids and their potential circulating targets.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Brain tumors are considered one of the deadliest types of cancer, being challenging to treat, especially due to the blood-brain barrier, which has been linked to treatment resistance. The genomic classification of brain tumors has been helping in the diagnostic precision, however tumor heterogeneity in addition to the difficulties to obtain tissue biopsies, represent a challenge. The biopsies are usually obtained either via neurosurgical removal or stereotactic tissue biopsy, which can be risky procedures for the patient. To overcome these challenges, liquid biopsy has become an interesting option by constituting a safer procedure than conventional biopsy, which may offer valuable cellular and molecular information representative of the whole organism. Besides, it is relatively easy to obtain such as in the case of blood (venipuncture) and urine sample collection. In the present comprehensive review, we discuss the newest information regarding liquid biopsy in the brain tumors’ field, methods employed, the different sources of bio-fluids and their potential circulating targets.

查看原文本刊更多论文

液体活检治疗中枢神经系统肿瘤的最新进展

脑肿瘤被认为是癌症最致命的类型之一，治疗起来很有挑战性，尤其是由于血脑屏障，这与治疗耐药性有关。脑肿瘤的基因组分类有助于提高诊断精度，然而，除了难以获得组织活检外，肿瘤的异质性也是一个挑战。活检通常通过神经外科切除或立体定向组织活检获得，这对患者来说可能是一种危险的手术。为了克服这些挑战，液体活检已经成为一种有趣的选择，因为它比传统活检更安全，可以提供代表整个生物体的有价值的细胞和分子信息。此外，它相对容易获得，例如在血液（静脉穿刺）和尿液样本采集的情况下。在本综述中，我们讨论了脑肿瘤领域中关于液体活检的最新信息、所采用的方法、生物液体的不同来源及其潜在的循环靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.